Our mission
Transform lives with therapeutic acute wound care.
Our strategy
Deliver high quality therapeutic acute wound care focused on advancing the treatment of burns, traumatic injuries, and other complex wounds through clinically validated technologies designed to support wound preparation, closure, and healing.
Our technologies
At the forefront of our platform is RECELL®, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. Across multiple product configurations, RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for definitive closure at point-of-care using minimal donor skin.
In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote re-epithelialization throughout the wound bed in a wide range of applications including burns and full-thickness skin defects. RECELL and RECELL GO® are CE-marked in Europe and have TGA-certification in Australia and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.
Our Values
We believe that patients are at the heart of everything we do.
We believe that our employees are the lifeblood of AVITA Medical.
We believe that passion is key to making a difference at AVITA Medical.
We believe that quality impacts everything we do.
We believe that integrity is essential to our success.
By the Numbers
230+
employees
25
clinical trials
850+
publications and abstracts
30,000+
patients treated worldwide